Cutting edge: Induction of the antigen-processing enzyme IFN-γ-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 731-735

  O'Donnell, Patrick W ^a   Haque, Azizul ^a   Klemsz, Michael J ^a   Kaplan, Mark H ^a   Blum, Janice S ^a  

^a Medical Science Building ^*

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE LYSOSOMAL THIOL REDUCTASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; OXIDOREDUCTASE; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CIITA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME BINDING; ENZYME INDUCTION; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 3142680216     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.731     Document Type: Article

References (39)

1. Pieters, J. 2000. MHC class II-restricted antigen processing and presentation. Adv. Immunol. 75:159.
2. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821.
3. West, M. A., J. M. Lucocq, and C. Watts. 1994. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 369:147.
4. Lennon-Dumenil, A. M., A. H. Bakker, P. Wolf-Bryant, H. L. Ploegh, and C. Lagaudriere-Gesbert. 2002. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr. Opin. Immunol. 14:15.
5. Harding, C. V. 1996. Class II antigen processing: analysis of compartments and functions. Crit. Rev. Immunol. 16:13.
6. Cresswell, P., B. Arunachalam, N. Bangia, T. Dick, G. Diedrich, E. Hughes, and M. Maric. 1999. Thiol oxidarion and reduction in MHC-restricted antigen processing and presentation. Immunol. Res. 19:191.
7. Collins, D., and C. Harding. 1991. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J. Immunol. 147:4054.
8. Li, P., M. A. Haque, and J. S. Blum. 2002. Role of disulfide bonds in regulating antigen processing and epitope selection. J. Immunol. 169:2444.
9. Short, S., B. J. Merkel, R. Caffrey, and K. L. McCoy. 1996. Defective antigen processing correlates with a low level of intracellular glutathione. Eur. J. Immunol 26:3015.
10. Arunachalam, B., U. T. Phan, H. J. Geuze, and P. Cresswell. 2000. Enzymatic reduction of disulfide bonds in lysosomes: characterization of γ-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA 97:745.
11. Luster, A. D., R. L. Weinshank, R. Feinman, and J. V. Ravetch. 1988. Molecular and biochemical characterization of a novel γ-interferon- inducible protein. J. Biol. Chem. 263:12036.
12. Haque, M. A., P. Li, S. K. Jackson, H. M. Zarour, J. W. Hawes, U. T. Phan, M. Maric, P. Cresswell, and J. S. Blum. 2002. Absence of γ-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J. Exp. Med. 195:1267.
13. Maric, M., B. Arunachalam, U. T. Phan, C. Dong, W. S. Garrett, K. S. Cannon, C. Alfonso, L. Karlsson, R. A. Flavell, and P. Cresswell. 2001. Defective antigen processing in GILT-free mice. Science 294:1361.
14. Phan, U. T., B. Arunachalam, and P. Cresswell. 2000. γ-Interferon- inducible lysosomal thiol reductase (GILT): maturation, activity, and mechanism of action. J. Biol. Chem. 275 25907.
15. Blum, J. S., C. Ma, and S. Kovats. 1997. Antigen-presenting cells and the selection of immumodominant epitopes. Crit. Rev. Immunol. 17:411.
16. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol 15:749.
17. Bach, E. A., M. Aguer, and R. D. Schreiber. 1997. THE IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563.
18. Shuai, K., G. R. Stark, I. M. Kerr, and J. E. Darnell, Jr. 1993. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 261:1744.
19. Levy, D. E., and J. E. Darnell. 2002. STATS: transcriptional control and biological impact. Nat. Rev. Mol Cell Biol. 3:651.
20. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
21. Dillman, R. O., R. K. Oldham, N. M. Barth, R. Birch, J. Arnold, and W. H. West. 1990. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J. Natl. Cancer Inst. 82:1345.
22. O'Rourke, M. G., C. W. Schmidt, T. R. O'Rourke, and K. A. Ellem. 1997. Immunotherapy, including gene therapy, for metastatic melanoma. Aust. Aurt. N. Z. J. Surg. 67:834.
23. + melanoma-infiltrating lymphocytes. Eur. J. Immunol 25:2732.
24. Rosenberg, S. 2001. Progress in human tumor immunology and immunotherapy. Nature 411:380.
25. Chang, C. H., T. S. Gourley, and T.J. Sisk. 2002. Function and regulation of class II transactiyator in the immune system. Immunol Res. 25:131.
26. Rigaud, G., A. De Lerma Barbaro, M. Nicolis, T. Cestari, D. Ramarli, A. P. Riviera, and R. S. Accolla. 1996. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-γ similarities and distinctions with respect to HLA-DR-constitutive B cells. J. cells. J. Immunol 156-4254.
27. Ting, J. P., and J. Trowsdale. 2002. Genetic control of MHC class II expression. Cell 109(Suppl.):S21.
28. Kovats, S., G. T. Nepom, M. Coleman, B. Nepom, W. W. Kwok, and J. S. Blum. 1995. Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome. J. Clin. Invest. 96:217.
29. Reith, W., and B. Mach. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19:331.
30. McKendry, R., J. John, D. Flavell, M. Muller, I. M. Kerr, and G. R. Stark. 1991. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both α and γ interferons. Proc. Natl. Acad. Sci. USA 88:11455.
31. Robbins, P. F., M. El-Gamil, Y. F. Li, G. Zeng, M. Dudley, and S. A. Rosenberg. 2002. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. 169:6036.
32. Bruns, H. A., U. Schindler, and M. H. Kaplan. 2003. Expression of a constitutively active Stata in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J. Immunol. 170:3478.
33. Morris, G. F., J. R. Bischoff, and M. B. Mathews. 1996. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad Sci. USA 93:895.
34. Ohmori, Y., and T. A. Hamilton. 2000. Interleukin-4/STAT6 represses STAT1 and NF-κB-dependent transcription through distinct mechanisms. J. Biol Chem. 275:38095.
35. Cramer, L. A., S. L. Nelson, and M. J. Klemsz. 2000. Synergistic induction of the Tap-1 gene by IFN-γ and lipopolysaccharide in macrophages is regulated by STAT1. J. Immunol. 165:3190.
36. Linebaugh, B. E., M. Sameni, N. A. Day, B. F. Sloane, and D. Keppler. 1999. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 264:100.
37. Billiau, A., H. Heremans, K. Vermeire, and P. Matthys. 1998. Immunomodulatory properties of interferon-γ an update. Ann. NY Acad. Sci. 856:22.
38. Schindler, C., X.Y. Fu, T. Improta, R. Aebersold, and J. E. Darnell, Jr. 1992. Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon α. Proc. Natl. Acad Sci. USA 89:7836.
39. Deffrennes, V., J. Vedrenne, M. C. Stolzenberg, J. Piskurich, G. Barbieri, J. P. Ting, D. Charron, and C. Alcaide-Loridan. 2001. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transctivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167:98